

## Analyst Group initiates coverage of Lumito

**Lumito AB (publ) ("Lumito" or the "Company") today announces that Analyst Group has initiated equity research coverage of Lumito, commissioned by the Company. The coverage includes equity research with quarterly updates as well as analyst comments on financial reports and press releases. Analyst Group's full equity research report on the Company is expected to be published in March 2026.**

Analyst Group's dedicated page for Lumito can be found [here](#).

"As Lumito continues to develop and take important steps on our growth journey, we see clear value in increasing our visibility in the capital markets. The collaboration with Analyst Group gives us the opportunity to communicate a clear and continuous picture of our operations, strategy, and long-term potential", says Sanna Wallenborg, CEO of Lumito.

### About Analyst Group

Analyst Group is a growing research firm focused on small- and micro-cap companies in Sweden. Since its founding in 2014, the company has developed deep expertise and experience in analyzing and providing equity research, while also helping companies improve their investor relations to increase understanding and transparency.

### For further information, please contact:

---

Sanna Wallenborg, CEO Lumito

E-mail: [sw@lumito.se](mailto:sw@lumito.se)

Ph: +4670-870 01 68

### About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. [www.lumito.se/en/](http://www.lumito.se/en/)

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

### Attachments

[Analyst Group initiates coverage of Lumito](#)